Ardelyx offers 28% revenue growth and a forward P/E of 11.0x with roughly 21-to-1 favorable risk/reward and 150% upside to analyst targets, yet business quality sitting just below the minimum floor constrains the position recommendation to avoid until quality metrics recover.
Thesis pillars
- Quality Below Minimum Floor→Stable
- Compelling Valuation Outsized Asymmetry→Stable
- Strong Revenue Growth Trajectory→Stable
- +1 more pillar — see the Why tab for full reasoning
Ardelyx, Inc. (ARDX) Stock Analysis
Falling Knife setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $5.28: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with... Read more
Sell if holding. Engine safety override at $5.28: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 39, MACD bearish. Score 6.0/10, moderate confidence.
Passes 6/9 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 31d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — Ardelyx, Inc.
Latest news
- NEWS Ladenburg Thalmann Assumes Ardelyx at Buy, Announces Price Target of $16 — benzinga Jun 16, 2026 positive
- NEWS Ardelyx Presents Data Analysis Evaluating Long-Term Impact Of XPHOZAH On Serum Electrolytes And Selected Nutrition Bioma — benzinga May 7, 2026 positive
- NEWS Ardelyx Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $94.473M Beat $92.655M Estimate — benzinga Apr 30, 2026 positive
- NEWS Earnings Scheduled For April 30, 2026 — benzinga Apr 30, 2026 neutral
Generated 2026-07-05T17:00:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.28: Quality below floor (3.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.0/10. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 39, MACD bearish. Prior stop was $4.90. Score 6.0/10, moderate confidence.
Take-profit target: $6.34 (+20.3% upside). Prior stop was $4.90. Stop-loss: $4.90.
DATA_ISSUE: analyst_target_implausible (raw $16.30 vs price $5.27 — ratio 3.1×). Rejected, falling back to technical TP.; Quality below floor (3.9 < 4.0).
Ardelyx, Inc. trades at a P/E of N/A (forward 10.2). TrendMatrix value score: 9.1/10. Verdict: Sell.
17 analysts cover ARDX with a consensus score of 4.5/5. Average price target: $16.
What does Ardelyx, Inc. do?Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and...
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 and is headquartered in Waltham, Massachusetts.